UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/577,655	05/01/2006	Kazuhiro Machida	0425-1257PUS1	3246
2292 7590 04/15/2010 BIRCH STEWART KOLASCH & BIRCH			EXAMINER	
PO BOX 747	CH, VA 22040-0747	EPPS -SMITH, JANET L		
FALLS CHUK	CII, VA 22040-0747		ART UNIT	PAPER NUMBER
			1633	
			NOTIFICATION DATE	DELIVERY MODE
			04/15/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

	Application No.	Applicant(s)					
	10/577,655	MACHIDA ET AL.					
Office Action Summary	Examiner	Art Unit					
	Janet L. Epps-Smith	1633					
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address					
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1)⊠ Responsive to communication(s) filed on <u>23 N</u>	ovember 2009.						
	action is non-final.						
· -							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1,3-6,12 and 14-31</u> is/are pending in the application.							
4a) Of the above claim(s) <u>3,6,12,14-16 and 24-31</u> is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1,4,5 and 21-23</u> is/are rejected.	· · · · · · · · · · · · · · · · · · ·						
7)⊠ Claim(s) <u>17-20</u> is/are objected to.							
8) Claim(s) are subject to restriction and/or	r election requirement.						
Application Papers							
9) The specification is objected to by the Examine	r						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correct		, ,					
11)☐ The oath or declaration is objected to by the Ex		• • •					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	-(d) or (f)					
a) All b) Some * c) None of:							
1.☐ Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da 5) Notice of Informal P						
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>1-21-10</u> .	6) Other:	aton Application					

Art Unit: 1633

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/23/2009 has been entered.

- 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 3. Claims 1, 3-6, 12, and 14-31 are pending.
- 4. Claims 3, 6, 12, 14-16, and 24-31 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention.
- 5. Claims 1, 4-5 and 17-23 are presently under examination.

Claim Rejections - 35 USC § 112

- 1. Claims 1, 4-5, and 21-23 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement.
- 2. Applicant's arguments filed 11-23-2009 have been fully considered but they are not persuasive. Applicants traversed the instant rejection on the grounds that the disclosure of PsmA, BpmA, and TpmA which share a high degree of conserved amino acids, is sufficient to demonstrate that Applicant's specification adequately complies with the written description requirement. The Examiner agrees that the specification

Art Unit: 1633

provides adequate written description for a DNA encoding a protein having enzymatic activity to hydroxylate the 16-position of the macrolide compound 11107B, wherein the DNA has "a nucleotide sequence having 90% or more identity over the full length sequence of nucleotides 1322 to 2548 of SEQ ID NO: 1. However, the scope of the instant claims encompass DNA molecules which comprise a nucleotide sequence having 90% or more identity over less than the entire sequence of nucleotides 1322 to 2548 of SEQ ID NO: 1. The specification as filed does not provide adequate support for DNA encoding a protein having enzymatic activity to hydroxylate the 16-position of the macrolide compound 11107B, wherein said sequence has 90% or more identity over less than the entire sequence of nucleotides 1322 to 2548 of SEQ ID NO: 1.

3. The rejection of claims 18 and 20 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, is withdrawn in response to Applicant's submission of a new sequence listing.

Claim Objections

4. Claims 17-20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Art Unit: 1633

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

- 6. Claims 1, 4-5 and 21-23 are rejected under 35 U.S.C. 102(b) as being anticipated by Nakajima et al. (WO2003040370A1, in Japanese, see English publication US2005/0084859 A1).
- 7. Claim 1 recites a DNA participating in biological transformation of a macrolide compound, the DNA being an isolated and pure DNA comprising a DNA encoding a protein having enzymatic activity to hydroxylate the 16-position of the macrolide compound 11107B, wherein the DNA has "a nucleotide sequence having 90% or more identity with nucleotides 1322 to 2548 of SEQ ID NO: 1. It is noted that the instant claims do not require 90% identity over the full length sequence of nucleotides 1322 to 2548 of SEQ ID NO: 1.
- 8. Nakajima et al. discloses the nucleotide sequence of SEQ ID NO: 237, which encodes an herbicide metabolizing protein. This nucleotide sequence has an overall identity of 85.5% identity with nucleotides 1322 to 2548 of SEQ ID NO: 1 of the instant application. However, there are multiple nucleotide sequences of SEQ ID NO: 237 that comprise 100% identity to nucleotides 1322 to 2548 of SEQ ID NO: 1. SEQ ID NO: 147 and 148 also share at least 84% identity to nucleotides 1322 to 2548 of SEQ ID NO: 1, and further comprise multiple nucleotide sequences having 100% identity to nucleotides 1322 to 2548 of SEQ ID NO: 1.
- 9. Nakajima et al. discloses a vector comprising the disclosed sequences, and transformants comprising said vector (see claims).

Art Unit: 1633

10. Absent evidence to the contrary, this disclosure of Nakajima et al. reads on the

instantly claimed invention.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Janet L. Epps-Smith whose telephone number is 571-

272-0757. The examiner can normally be reached on M-F, 10:00 AM through 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Joseph Woitach can be reached on 571-272-0739. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Janet L. Epps-Smith/

Primary Examiner, Art Unit 1633

Application/Control Number: 10/577,655

Page 6

Art Unit: 1633